Literature DB >> 25940197

Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.

Ana Paula Gruendling1, Miyoko Massago1, Ana Paula M Teston1, Wuelton M Monteiro1, Edilson N Kaneshima1, Silvana M Araújo1, Mônica L Gomes1, Maria das Graças V Barbosa1, Max Jean O Toledo2.   

Abstract

American trypanosomiasis is an emerging zoonosis in the Brazilian Amazon. Studies on benznidazole (BZ) chemotherapy with Trypanosoma cruzi from this region have great relevance, given the different discrete typing units (DTUs) that infect humans in the Amazon and other regions of Brazil. We performed a parasitological, histopathological, and molecular analysis of mice inoculated with strains of T. cruzi I, II, and IV that were BZ-treated during the acute phase of infection. Groups of Swiss mice were inoculated; 13 received oral BZ, whereas the other 13 comprised the untreated controls. Unlike parasitemia, the infectivity and mortality did not vary among the DTUs. Trypanosoma cruzi DNA was detected in all tissues analyzed and the proportion of organs parasitized varied with the parasite DTU. The BZ treatment reduced the most parasitological parameters, tissue parasitism and the inflammatory processes at all infection stages and for all DTUs. However, the number of significant reductions varied according to the DTU and infection phase. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25940197      PMCID: PMC4458823          DOI: 10.4269/ajtmh.13-0690

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  39 in total

1.  Nucleotide sequences provide evidence of genetic exchange among distantly related lineages of Trypanosoma cruzi.

Authors:  C A Machado; F J Ayala
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

2.  Trypanosoma cruzi: paninfectivity of CL strain during murine acute infection.

Authors:  H L Lenzi; D N Oliveira; M T Lima; C R Gattass
Journal:  Exp Parasitol       Date:  1996-10       Impact factor: 2.011

3.  Trypanosoma cruzi I-III in southern Brazil causing individual and mixed infections in humans, sylvatic reservoirs and triatomines.

Authors:  Nilce Gomes Abolis; Silvana Marques de Araújo; Max Jean de Ornelas Toledo; Maria Aparecida Fernandez; Mônica Lúcia Gomes
Journal:  Acta Trop       Date:  2011-08-09       Impact factor: 3.112

Review 4.  Risks of endemicity, morbidity and perspectives regarding the control of Chagas disease in the Amazon Region.

Authors:  José Rodrigues Coura; Angela Cv Junqueira
Journal:  Mem Inst Oswaldo Cruz       Date:  2012-03       Impact factor: 2.743

5.  Trypanosoma cruzi: biological characterization of a isolate from an endemic area and its susceptibility to conventional drugs.

Authors:  Noelia L Grosso; Jacqueline Bua; Alina E Perrone; Mariela N Gonzalez; Patricia L Bustos; Miriam Postan; Laura E Fichera
Journal:  Exp Parasitol       Date:  2010-05-21       Impact factor: 2.011

6.  Differential tissue tropism of Trypanosoma cruzi strains: an in vitro study.

Authors:  Luciana O Andrade; Lúcia M C Galvão; Maria de Nazareth S L Meirelles; Egler Chiari; Sergio D J Pena; Andrea M Macedo
Journal:  Mem Inst Oswaldo Cruz       Date:  2010-09       Impact factor: 2.743

7.  [Acute phase of Chagas disease in the Brazilian Amazon region: study of 233 cases from Pará, Amapá and Maranhão observed between 1988 and 2005].

Authors:  Ana Yecê das Neves Pinto; Sebastião Aldo Valente; Vera da Costa Valente; Alberto Gomes Ferreira Junior; José Rodrigues Coura
Journal:  Rev Soc Bras Med Trop       Date:  2008 Nov-Dec       Impact factor: 1.581

8.  In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon.

Authors:  Ana P M Teston; Wuelton M Monteiro; Daniele Reis; Gleison D P Bossolani; Mônica L Gomes; Silvana M de Araújo; Maria T Bahia; Maria G V Barbosa; Max J O Toledo
Journal:  Trop Med Int Health       Date:  2012-11-06       Impact factor: 2.622

9.  Trypanosoma cruzi I and IV stocks from Brazilian Amazon are divergent in terms of biological and medical properties in mice.

Authors:  Wuelton Marcelo Monteiro; Ana Paula Margioto Teston; Ana Paula Gruendling; Daniele dos Reis; Mônica Lúcia Gomes; Silvana Marques de Araújo; Maria Terezinha Bahia; Laylah Kelre Costa Magalhães; Jorge Augusto de Oliveira Guerra; Henrique Silveira; Max Jean de Ornelas Toledo; Maria das Graças Vale Barbosa
Journal:  PLoS Negl Trop Dis       Date:  2013-02-21

10.  International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients.

Authors:  Alejandro G Schijman; Margarita Bisio; Liliana Orellana; Mariela Sued; Tomás Duffy; Ana M Mejia Jaramillo; Carolina Cura; Frederic Auter; Vincent Veron; Yvonne Qvarnstrom; Stijn Deborggraeve; Gisely Hijar; Inés Zulantay; Raúl Horacio Lucero; Elsa Velazquez; Tatiana Tellez; Zunilda Sanchez Leon; Lucia Galvão; Debbie Nolder; María Monje Rumi; José E Levi; Juan D Ramirez; Pilar Zorrilla; María Flores; Maria I Jercic; Gladys Crisante; Néstor Añez; Ana M De Castro; Clara I Gonzalez; Karla Acosta Viana; Pedro Yachelini; Faustino Torrico; Carlos Robello; Patricio Diosque; Omar Triana Chavez; Christine Aznar; Graciela Russomando; Philippe Büscher; Azzedine Assal; Felipe Guhl; Sergio Sosa Estani; Alexandre DaSilva; Constança Britto; Alejandro Luquetti; Janis Ladzins
Journal:  PLoS Negl Trop Dis       Date:  2011-01-11
View more
  12 in total

1.  Limit of detection of PCR/RFLP analysis of cytochrome oxidase II for the identification of genetic groups of Trypanosoma cruzi and Trypanosoma rangeli in biological material from vertebrate hosts.

Authors:  Amanda Regina Nichi Sá; Karen Yuki Kimoto; Mário Steindel; Edmundo Carlos Grisard; Mônica Lúcia Gomes
Journal:  Parasitol Res       Date:  2018-06-01       Impact factor: 2.289

2.  Mice Intragastric Infected with Insect and Blood Trypomastigotes of Trypanosoma cruzi IV: Differences and Similarities on the Evolution Profile and Response to Etiological Treatment.

Authors:  Miyoko Massago; Gerson Zanusso Junior; Elaine Schultz Dworak; Elisama Loubak da Silva; Alexandre Tadachi Morey; Mônica Lúcia Gomes; Max Jean de Ornelas Toledo
Journal:  Acta Parasitol       Date:  2021-04-23       Impact factor: 1.440

3.  Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.

Authors:  Ágata Carolina Cevey; Gerardo Ariel Mirkin; Federico Nicolás Penas; Nora Beatriz Goren
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2015-12-12       Impact factor: 4.077

Review 4.  Chagas disease research and development: Is there light at the end of the tunnel?

Authors:  Eric Chatelain
Journal:  Comput Struct Biotechnol J       Date:  2016-12-14       Impact factor: 7.271

Review 5.  Biological factors that impinge on Chagas disease drug development.

Authors:  Amanda F Francisco; Shiromani Jayawardhana; Michael D Lewis; Martin C Taylor; John M Kelly
Journal:  Parasitology       Date:  2017-08-23       Impact factor: 3.234

6.  A multi-parametric analysis of Trypanosoma cruzi infection: common pathophysiologic patterns beyond extreme heterogeneity of host responses.

Authors:  Julien Santi-Rocca; Fernando Fernandez-Cortes; Carlos Chillón-Marinas; María-Luisa González-Rubio; David Martin; Núria Gironès; Manuel Fresno
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

7.  Germacranolide-type sesquiterpene lactones from Smallanthus sonchifolius with promising activity against Leishmania mexicana and Trypanosoma cruzi.

Authors:  Jerónimo L Ulloa; Renata Spina; Agustina Casasco; Patricia B Petray; Virginia Martino; Miguel A Sosa; Fernanda M Frank; Liliana V Muschietti
Journal:  Parasit Vectors       Date:  2017-11-13       Impact factor: 3.876

8.  The diversity of the Chagas parasite, Trypanosoma cruzi, infecting the main Central American vector, Triatoma dimidiata, from Mexico to Colombia.

Authors:  Patricia L Dorn; Annie G McClure; Meghan D Gallaspy; Etienne Waleckx; Adrienne S Woods; Maria Carlota Monroy; Lori Stevens
Journal:  PLoS Negl Trop Dis       Date:  2017-09-28

9.  Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.

Authors:  Amanda Fortes Francisco; Shiromani Jayawardhana; Michael D Lewis; Karen L White; David M Shackleford; Gong Chen; Jessica Saunders; Maria Osuna-Cabello; Kevin D Read; Susan A Charman; Eric Chatelain; John M Kelly
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

Review 10.  Challenges in Chagas Disease Drug Development.

Authors:  Amanda F Francisco; Shiromani Jayawardhana; Francisco Olmo; Michael D Lewis; Shane R Wilkinson; Martin C Taylor; John M Kelly
Journal:  Molecules       Date:  2020-06-17       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.